Kaposiform Hemangioendothelioma
8
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
Identification of Biomarkers for Patients with Vascular Anomalies
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma